Lv6
1800 积分 2023-03-03 加入
Bispecific aptamers target thyrotropin receptor (TSHR) and insulin growth factor-1 receptor (IGF-1R) for the improvement of orbital fibroblasts activation in the treatment of thyroid-associated ophthalmopathy
5天前
已完结
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma
27天前
已完结
Dual-payload ADCs move into first oncology clinical trials
1个月前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
1个月前
已完结
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
1个月前
已完结
Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8+ T cell and evading IL-18BP in preclinical models
1个月前
已完结
678 - Patient-reported outcomes for GSK1070806, an anti-IL-18 monoclonal antibody: a phase 1b, randomised, double-blind, parallel-group placebo-controlled study of patients with atopic dermatitis
1个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin- 18 mAb GSK1070806 in healthy and obese subjects
1个月前
已完结
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials
2个月前
已完结
皖公网安备34019202002308
